RD3 loss dictates high-risk aggressive neuroblastoma and poor clinical outcomes

Clinical outcomes for high-risk neuroblastoma patients remains poor, with only 40–50% 5-Year overall survival (OS) and <10% long-term survival. The ongoing acquisition of genetic/molecular rearrangements in undifferentiated neural crest cells may endorse neuroblastoma progression. This study reco...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Khan, Faizan H., Pandian, Vijayabaskar, Ramraj, Satish Kumar, Aravindan, Sheeja, Natarajan, Mohan, Azadi, Seifollah, Herman, Terence S., Aravindan, Natarajan
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2015
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4742193/
https://ncbi.nlm.nih.gov/pubmed/26375249
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados